These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20031009)

  • 1. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment.
    Hay J; Jhaveri M; Tangirala M; Kaliner M
    Allergy Asthma Proc; 2009; 30(6):634-42. PubMed ID: 20031009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost and utilization impacts of oral antihistamines in the California Medi-Cal program.
    Hay JW; Leahy M
    Value Health; 2005; 8(4):506-16. PubMed ID: 16091028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population.
    Bollinger ME; Diette GB; Chang CL; Stephenson JJ; Sajjan SG; Fan T; Allen-Ramey FC
    Clin Ther; 2010 Jun; 32(6):1093-102. PubMed ID: 20637964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis: PRAACTICAL study.
    Dal Negro R; Piskorz P; Vives R; Guilera M; Sazonov Kocevar V; Badia X
    Pharmacoeconomics; 2007; 25(8):665-76. PubMed ID: 17640108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seasonal versus perennial allergic rhinitis: drug and medical resource use patterns.
    Crown WH; Olufade A; Smith MW; Nathan R
    Value Health; 2003; 6(4):448-56. PubMed ID: 12859586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental healthcare utilization and expenditures for allergic rhinitis in the United States.
    Bhattacharyya N
    Laryngoscope; 2011 Sep; 121(9):1830-3. PubMed ID: 21997726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective.
    Hay JW; Kaliner MA
    Curr Med Res Opin; 2009 Jun; 25(6):1421-31. PubMed ID: 19422280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy.
    Luskin A; Bukstein D; Kocevar VS; Yin DD
    Ann Allergy Asthma Immunol; 2005 Aug; 95(2):129-36. PubMed ID: 16136761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health care resource use and associated costs among patients with seasonal versus perennial allergic rhinitis.
    Lang K; Allen-Ramey F; Huang H; Rock M; Kaufman E; Dykewicz MS
    Allergy Asthma Proc; 2016 Sep; 37(5):103-11. PubMed ID: 27657517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asthma and allergy medication use and costs among pediatric primary care patients on asthma controller therapy.
    Sazonov-Kocevar V; Laforest L; Travier N; Yin DD; Van Ganse E
    Pediatr Allergy Immunol; 2006 Dec; 17(8):620-8. PubMed ID: 17121591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic consequences of comorbid depression, anxiety, and allergic rhinitis.
    Cuffel B; Wamboldt M; Borish L; Kennedy S; Crystal-Peters J
    Psychosomatics; 1999; 40(6):491-6. PubMed ID: 10581977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allergen immunotherapy and health care cost benefits for children with allergic rhinitis: a large-scale, retrospective, matched cohort study.
    Hankin CS; Cox L; Lang D; Bronstone A; Fass P; Leatherman B; Wang Z
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):79-85. PubMed ID: 20143650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost of productivity losses associated with allergic rhinitis.
    Crystal-Peters J; Crown WH; Goetzel RZ; Schutt DC
    Am J Manag Care; 2000 Mar; 6(3):373-8. PubMed ID: 10977437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis.
    Liao E; Leahy M; Cummins G
    Am J Manag Care; 2001 Oct; 7(15 Suppl):S459-68. PubMed ID: 11680261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allergic rhinitis--an epidemiological, economical and social problem of the XXI century].
    Rutkowski R; Kosztyła-Hojna B; Rutkowska J
    Pneumonol Alergol Pol; 2008; 76(5):348-52. PubMed ID: 19003765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergic rhinitis.
    Ciebiada M; Górska-Ciebiada M; DuBuske LM; Górski P
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):664-71. PubMed ID: 17165277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey.
    Law AW; Reed SD; Sundy JS; Schulman KA
    J Allergy Clin Immunol; 2003 Feb; 111(2):296-300. PubMed ID: 12589348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes and cost comparison of three therapeutic approaches to allergic rhinitis.
    Fairchild CJ; Durden E; Cao Z; Smale P
    Am J Rhinol Allergy; 2011; 25(4):257-62. PubMed ID: 21639996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of allergic rhinitis in Korea.
    Kim SY; Yoon SJ; Jo MW; Kim EJ; Kim HJ; Oh IH
    Am J Rhinol Allergy; 2010; 24(5):e110-3. PubMed ID: 21244726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment with montelukast and levocetirizine combination in persistent allergic rhinitis: review of recent evidence.
    Adsule SM; Misra D
    J Indian Med Assoc; 2010 Jun; 108(6):381-2. PubMed ID: 21121394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.